Holen Sie sich die Stockscreener-App
81.84
3.17%
-2.77
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt EW?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$84.61
Offen:
$85.13
24-Stunden-Volumen:
2.43M
Relative Volume:
0.59
Marktkapitalisierung:
$47.52B
Einnahmen:
$6.07B
Nettoeinkommen (Verlust:
$1.06B
KGV:
45.31
EPS:
1.8063
Netto-Cashflow:
$1.34B
1W Leistung:
+0.35%
1M Leistung:
+7.99%
6M Leistung:
+5.62%
1J Leistung:
+20.57%
1-Tages-Spanne:
$81.47
$85.33
1-Wochen-Bereich:
$80.54
$86.38
52-Wochen-Spanne:
$65.94
$87.89
Edwards Lifesciences Corp Stock (EW) Company Profile
Firmenname
Edwards Lifesciences Corp
Sektor
Branche
Telefon
(949) 250-2500
Adresse
ONE EDWARDS WAY, IRVINE, CA
Compare EW vs ABT, SYK, MDT, BSX
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
81.83 | 49.14B | 6.07B | 1.06B | 1.34B | 1.8063 |
|
ABT
Abbott Laboratories
|
108.82 | 187.91B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
340.20 | 129.05B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
87.59 | 112.19B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
69.12 | 101.72B | 20.08B | 2.89B | 3.66B | 1.9391 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-09 | Hochstufung | TD Cowen | Hold → Buy |
| 2025-12-18 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-11-03 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2025-10-29 | Hochstufung | Jefferies | Hold → Buy |
| 2025-10-29 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2025-10-08 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-10-07 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-07-29 | Hochstufung | BTIG Research | Neutral → Buy |
| 2025-04-24 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-01-30 | Hochstufung | Stifel | Hold → Buy |
| 2025-01-16 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-12-16 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-11 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2024-09-18 | Herabstufung | Jefferies | Buy → Hold |
| 2024-07-31 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-07-29 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2024-07-25 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-07-25 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-25 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-07-25 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-07-25 | Herabstufung | Truist | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-05-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-05-14 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-03-07 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-02-02 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-01-04 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-11-28 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2023-09-26 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Overweight |
| 2023-03-29 | Eingeleitet | UBS | Neutral |
| 2023-03-08 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-02-06 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-01-31 | Herabstufung | Bernstein | Outperform → Underperform |
| 2023-01-30 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-12-06 | Herabstufung | Stifel | Buy → Hold |
| 2022-10-28 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-10-26 | Eingeleitet | Mizuho | Buy |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-29 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2022-04-13 | Eingeleitet | Truist | Buy |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-03-16 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Neutral |
| 2022-02-02 | Hochstufung | UBS | Neutral → Buy |
| 2022-01-27 | Bestätigt | Citigroup | Buy |
| 2022-01-27 | Bestätigt | Evercore ISI | Outperform |
| 2022-01-27 | Bestätigt | Raymond James | Outperform |
| 2022-01-27 | Bestätigt | Stifel | Buy |
| 2022-01-27 | Bestätigt | UBS | Neutral |
| 2021-12-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-12-15 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-12-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2021-07-30 | Bestätigt | Canaccord Genuity | Buy |
| 2021-07-30 | Bestätigt | Deutsche Bank | Hold |
| 2021-07-30 | Bestätigt | Jefferies | Buy |
| 2021-07-30 | Bestätigt | Morgan Stanley | Overweight |
| 2021-07-30 | Bestätigt | Oppenheimer | Outperform |
| 2021-07-30 | Bestätigt | Stifel | Buy |
| 2021-07-30 | Bestätigt | UBS | Neutral |
| 2021-07-30 | Bestätigt | Wells Fargo | Equal Weight |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Neutral |
| 2021-04-05 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-11 | Bestätigt | Canaccord Genuity | Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Underperform |
| 2020-04-28 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Neutral |
| 2020-01-10 | Eingeleitet | Oppenheimer | Outperform |
| 2020-01-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-10-24 | Bestätigt | Canaccord Genuity | Buy |
| 2019-09-23 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-07-24 | Bestätigt | BofA/Merrill | Buy |
| 2019-03-18 | Bestätigt | Canaccord Genuity | Buy |
| 2019-01-18 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-01-03 | Eingeleitet | Deutsche Bank | Hold |
| 2018-11-28 | Eingeleitet | UBS | Neutral |
| 2018-10-16 | Eingeleitet | Barclays | Underweight |
| 2018-10-02 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-10-02 | Herabstufung | Guggenheim | Buy → Neutral |
Alle ansehen
Edwards Lifesciences Corp Aktie (EW) Neueste Nachrichten
Connor Clark & Lunn Investment Management Ltd. Has $42.22 Million Stake in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corporation $EW Shares Bought by Bank of Montreal Can - MarketBeat
WINTON GROUP Ltd Sells 57,665 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Natixis Advisors LLC Grows Stock Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
Grantham Mayo Van Otterloo & Co. LLC Acquires New Position in Edwards Lifesciences Corporation $EW - MarketBeat
A Look At Edwards Lifesciences (EW) Valuation As It Exits Critical Care To Focus On Core Heart Therapies - simplywall.st
Insider Sell: Daniel Lippis Sells Shares of Edwards Lifesciences Corp (EW) - GuruFocus
Edwards Lifesciences Hits Day High with Strong 3.21% Intraday Surge - Markets Mojo
Edwards Lifesciences at Leerink Conference: Strategic Growth and Innovation - Investing.com
Edwards Lifesciences Corporation $EW Shares Sold by Swiss National Bank - MarketBeat
Edwards Lifesciences at Barclays: Strategic Growth Focus - Investing.com
Edwards Lifesciences at Barclays Conference: Strategic Growth Focus By Investing.com - Investing.com Canada
Edwards Lifesciences at Barclays Conference: Strategic Growth Focus - Investing.com
Korea Investment CORP Purchases 46,317 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corporation (NYSE:EW) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Edwards Lifesciences jumps 3.21% with $400M traded, placing 368th in volume; revenue growth exceeds earnings shortfall - Bitget
Is Edwards Lifesciences Stock Outperforming the S&P 500? - inkl
Niranjan Pai joins Edwards Lifesciences as Director-Government Affairs - Exchange4Media
Inceptionr LLC Makes New $1.61 Million Investment in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corporation $EW Shares Acquired by Russell Investments Group Ltd. - MarketBeat
Rathbones Group PLC Has $6.84 Million Position in Edwards Lifesciences Corporation $EW - MarketBeat
Rhenman & Partners Asset Management AB Has $12.05 Million Stock Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
Blair William & Co. IL Has $28.96 Million Stock Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
How Edwards Lifesciences Corporation stock performs during Fed tightening cyclesJuly 2025 Weekly Recap & Consistent Profit Alerts - Naître et grandir
Edwards Lifesciences Corp (EW) Trading Down 3.41% on Mar 6 - GuruFocus
Fisher Asset Management LLC Cuts Stake in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Edwards Lifesciences Corporation $EW Shares Acquired by Elo Mutual Pension Insurance Co - MarketBeat
Edwards Lifesciences (EW) Valuation Check After FDA Nod For SAPIEN M3 And 2026 Growth Outlook - simplywall.st
Edwards Lifesciences (NYSE:EW) VP Sells $974,446.20 in Stock - MarketBeat
Edwards Lifesciences Corp Officer Sells Shares - TradingView
Edwards Lifesciences at TD Cowen Conference: Strategic Growth and Innovation - Investing.com
Why Investors Are Eyeing Edwards Lifesciences Corp (EW): The Key - GuruFocus
Intech Investment Management LLC Increases Stake in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences (EW) Is Up 8.4% After SAPIEN M3 FDA Win And FTC SetbackHas The Bull Case Changed? - simplywall.st
Huntington National Bank Sells 14,023 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Erste Asset Management GmbH Lowers Stock Position in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Hits Day High with Strong 3% Intraday Surge - Markets Mojo
TD Asset Management Inc Sells 12,562 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Insider Sold Shares Worth $2,012,076, According to a Recent SEC Filing - marketscreener.com
Edwards Lifesciences CVP Bobo sells $2m in stock - Investing.com Nigeria
Edwards Lifesciences (NYSE: EW) VP sells 24,000 common shares - Stock Titan
Edwards Lifesciences Corp Officer Sells 24,000 Shares - TradingView
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch
[144] Edwards Lifesciences Corp SEC Filing - Stock Titan
Edwards Lifesciences at Citi’s MedTech Day: Optimism in Growth Strategies - Investing.com
10 Health Care Stocks Whale Activity In Today's Session - Benzinga
Edwards Lifesciences plans to reach 2M underserved heart patients by 2030 - Stock Titan
How The Edwards Lifesciences (EW) Investment Story Is Shifting After Mixed Analyst Revisions - Yahoo Finance
Decoding Edwards Lifesciences Corp (EW): A Strategic SWOT Insigh - GuruFocus
Edwards Lifesciences Hits Day High with Strong 3.28% Intraday Surge - Markets Mojo
Finanzdaten der Edwards Lifesciences Corp-Aktie (EW)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
1.30%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):